药物疗法对亚阈值腹主动脉瘤生长与死亡影响的网状Meta分析
结果显示各药物组与安慰剂组在瘤体生长、手术转诊率和总体死亡率上均无显著差异,但普萘洛尔和替格瑞洛因不良事件停药率较高。证据质量多为中等,现有数据可能把握度不足。
要点
- 亚阈值腹主动脉瘤药物疗法未显示显著延缓瘤体生长或降低死亡率。
- 普萘洛尔和替格瑞洛因不良事件停药风险显著增高。
- 现有证据多为中等质量,需更大样本随机对照试验验证。
核心结论
- 当前证据表明药物疗法对亚阈值腹主动脉瘤生长率、手术转诊率或总体死亡率的影响仍不确定。
- 无显著获益可能反映数据集把握度不足,而非 definitively 无效。
研究设计与样本
- 检索MEDLINE、Scopus、Web of Science、EBSCO和Cochrane Library从建库至2024年。
- 干预组腹主动脉瘤直径3.1-4.6 cm,安慰剂组3.5-4.5 cm。
主要发现
- 研究水平平均年生长率干预组1.2-2.8 mm/年,安慰剂组1.2-2.6 mm/年。
- 各组腹主动脉瘤生长无显著差异,P评分:普萘洛尔0.73、替米沙坦0.66、抗生素0.53、安慰剂0.53、ACE抑制剂0.52、替格瑞洛0.46、吡嘧司特0.06。
- 手术转诊率无显著差异,P评分:普萘洛尔0.91、抗生素0.56、安慰剂0.45、吡嘧司特0.08。
- 总体死亡率无显著差异,P评分:替米沙坦0.87、抗生素0.57、ACE抑制剂0.51、安慰剂0.35、普萘洛尔0.17。
- 普萘洛尔(OR=3.14,95%CI 1.34-7.35)和替格瑞洛(OR=5.10,95%CI 1.12-23.18)因不良事件停药率较高。
关键数值与推荐
- 指南建议腹主动脉瘤直径达阈值(女性50 mm或男性55 mm)或快速扩张(>5 mm/年)时行手术管理。
- GRADE框架评估多数研究为中等质量证据。
临床怎么用
- 对于亚阈值腹主动脉瘤,现有药物疗法缺乏显著获益证据,不应常规用于延缓瘤体生长。
- 使用普萘洛尔或替格瑞洛时需警惕不良事件导致的停药风险。
局限性
- 缺乏统计学显著获益可能反映数据集把握度不足。
- 需要未来大规模、把握度适当的随机对照试验评估新兴药物治疗的临床潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Abdominal aortic aneurysm (AAA) is often fatal when ruptured, and current guidelines suggest surgical management at suprathreshold sizes (50 mm for women or 55 mm for men) or with rapid expansion (>5 mm/year). Many medical therapies have been assessed for reducing subthreshold AAA expansion, though the evidence remains inconclusive. This network meta-analysis (NMA) compares AAA growth and mortality amongst medical treatments for AAAs. METHODS: MEDLINE (via PubMed), Scopus, Web of Science, EBSCO, and Cochrane Library databases were searched for relevant randomized controlled trials (RCTs) from database inception to 2024. Outcomes assessed included AAA growth rate, rate of referral for aneurysm surgery, overall mortality, and discontinuation from adverse effects. Data were analysed using R software, and P-score were used to rank different treatments. The GRADE framework was performed to assess the quality of evidence. RESULTS: Thirteen RCTs comprising 3084 patients were included in this NMA. Abdominal aortic aneurysm diameters ranged from 3.1 to 4.6 cm in the intervention group and 3.5-4.5 cm in the placebo group. Study-level mean annual growth rate ranged from 1.2 to 2.8 mm/year in the intervention group compared with placebo (1.2-2.6 mm/year). There were no significant differences in AAA growth among the compared groups (P-score probability in brackets): propranolol (0.73), telmisartan (0.66), antibiotics (0.53), placebo (0.53), ACE inhibitors (0.52), ticagrelor (0.46), and pemirolast (0.06). There were no significant differences among the compared groups in terms of aneurysm surgery referral rates, with propranolol (0.91), antibiotics (0.56), placebo (0.45), and pemirolast (0.08) showing similar outcomes. Similarly, no significant differences were observed in overall mortality rates across the groups, including telmisartan (0.87), antibiotics (0.57), ACE inhibitors (0.51), placebo (0.35), and propranolol (0.17). However, propranolol (OR = 3.14, 95% CI, 1.34-7.35) and ticagrelor (OR = 5.10, 95% CI, 1.12-23.18) were associated with a higher rate of discontinuation due to adverse events. Most of the studies analysed demonstrated moderate quality evidence. CONCLUSIONS: Current evidence highlights ongoing uncertainty regarding the efficacy of medical therapies in reducing subthreshold AAA growth rates, rates of referral for surgical repair, or overall mortality. The absence of statistically significant benefit may reflect underpowered datasets rather than definitive treatment inefficacy. Future large-scale, appropriately powered RCTs evaluating emerging medical treatments are required to accurately assess their clinical potential.
引用
- Lu PYJ, Seth I, Fung CHC, et al. The Effect of Medical Therapies for Subthreshold Abdominal Aortic Aneurysm Growth and Mortality: A Network Meta-Analysis of Randomized Controlled Trials. Interdiscip Cardiovasc Thorac Surg. 2026. PMID: 41875387. doi:10.1093/icvts/ivag088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。